8-K: Novavax Secures FDA Approval for Nuvaxovid, Triggering $175 Million Milestone Payment from Sanofi

Novavax receives FDA approval for its COVID-19 vaccine Nuvaxovid, triggering a $175 million milestone payment from Sanofi and prompting a new postmarketing commitment (PMC) trial.

Summary

• Novavax announced that the FDA has approved its Biologics License Application (BLA) for Nuvaxovid, its COVID-19 vaccine, for adults 65 years and older and individuals 12 through 64 years with at least one underlying condition.
• The FDA approval triggers a $175 million milestone payment from Sanofi under the Collaboration and License Agreement signed in May 2024.
• The FDA has requested a new postmarketing commitment (PMC) to conduct a Phase 4 trial in individuals aged 50 through 64 without high-risk conditions.
• Novavax expects to be ready for commercial delivery of the 2025-2026 COVID-19 vaccine formula in the U.S. this Fall, pending strain recommendation at the FDA meeting on May 22, 2025.
• Novavax reiterates its expectation to achieve R&D plus SG&A expenses for full year 2025 of between $475 and $525 million.
• For 2026 and 2027, Novavax expects to reduce its R&D and SG&A expenses to approximately $350 million and approximately $250 million, respectively.

Sentiment

Score: 7

Explanation: The FDA approval and milestone payment are positive developments, but the new PMC trial introduces uncertainty and additional costs. The planned reduction in expenses is a positive sign, but the company faces risks related to manufacturing, regulatory approvals, and competition.

Positives

• FDA approval of Nuvaxovid validates Novavax's vaccine technology.
• The $175 million milestone payment from Sanofi strengthens Novavax's financial position.
• The expected commercial delivery of the 2025-2026 COVID-19 vaccine formula in the U.S. this Fall provides a potential revenue stream.
• Planned reductions in R&D and SG&A expenses in 2026 and 2027 indicate a focus on cost management.

Negatives

• The FDA's request for a new postmarketing commitment (PMC) trial adds to Novavax's expenses and workload.
• The company is working closely with Sanofi to assess funding and execution of the new PMC trial, which introduces uncertainty.

Risks

• Challenges or delays related to the requested PMC or in obtaining further regulatory authorization for its COVID-19 vaccine, including approval of the sBLA, could impact future revenue.
• Antigenic drift or shift in the SARS-CoV-2 spike protein could reduce the efficacy of the vaccine.
• Manufacturing, distribution or export delays or challenges could affect the delivery of customer orders.
• Novavax's exclusive dependence on Serum Institute of India Pvt. Ltd. for co-formulation and filling poses a risk if their operations are disrupted.

Future Outlook

Novavax anticipates commercial delivery of the 2025-2026 COVID-19 vaccine formula in the U.S. this Fall and expects to reduce R&D and SG&A expenses in 2026 and 2027. The company intends to further clarify its financial guidance as trial execution discussions with Sanofi are finalized.

Industry Context

The FDA approval of Nuvaxovid positions Novavax to compete in the COVID-19 vaccine market alongside established players like Pfizer and Moderna. The collaboration with Sanofi is a strategic move to leverage Sanofi's commercial infrastructure and expertise.

Comparison to Industry Standards

• Pfizer and Moderna, leading competitors in the COVID-19 vaccine market, have demonstrated high efficacy rates with their mRNA vaccines.
• Novavax's Nuvaxovid offers a protein-based alternative, which may appeal to individuals hesitant about mRNA technology.
• The postmarketing commitment (PMC) requested by the FDA is a standard requirement for vaccine approvals, ensuring ongoing monitoring of safety and efficacy.
• The collaboration with Sanofi mirrors similar partnerships in the pharmaceutical industry, where companies combine their strengths to develop and commercialize products.

Stakeholder Impact

• Shareholders will likely react positively to the FDA approval and milestone payment.
• Employees may experience increased workload due to the new PMC trial.
• Customers (healthcare providers and patients) will have another COVID-19 vaccine option.
• Sanofi will benefit from the collaboration by expanding its vaccine portfolio.

Next Steps

• Finalize trial execution discussions with Sanofi regarding the new PMC.
• Prepare for commercial delivery of the 2025-2026 COVID-19 vaccine formula in the U.S. this Fall.
• File a supplemental BLA (sBLA) for the 2025-2026 vaccination season.
• Monitor strain recommendations at the FDA Vaccines and Related Biological Products Advisory Committee meeting on May 22, 2025.

Key Dates

Keywords

Nuvaxovid, COVID-19 vaccine, FDA approval, Sanofi, Postmarketing commitment, PMC trial, R&D expenses, SG&A expenses, Milestone payment, Regulatory authorization